Global Ischemic stroke Treatment Market - 2023-2030

Overview

An ischemic stroke emerges when the blood supply to region of the brain is interrupted or decreased, stopping brain tissue from obtaining oxygen and nutrients. Brain cells start to die in minutes. A stroke is a medical crisis, and immediate attention is necessary. Premature action can lessen brain injury and additional intricacies.

The primary treatment for an ischemic stroke is a drug called tissue plasminogen activator (tPA). It busts up the blood clots that obstruct blood flow to the brain. A healthcare provider injects tPA into a vein in the arm. The drug is highly beneficial if given within 3 hours post-stroke manifestations begin.

Market Dynamics: Drivers & Restraints

Growing Prevalence

The rising events of brain stroke and aneurysms are expected to drive the growth of the global market in the coming years. As per the statistics provided by the World Stroke Organization, stroke has already reached epidemic proportions, with one out of four adults above the age of 25 expected to experience a stroke in their lifetime. It is estimated that over 12.2 million individuals worldwide will face their first stroke this year, and 6.5 million will succumb to it.

Additionally, brain aneurysm affects approximately 3.0% of people in the U.K., and the Brain Aneurysm Foundation has reported that more than 6.0 million Americans are affected by brain aneurysms every year. Furthermore, growing awareness and research activites among other factors are also expected to contribute to the global market growth during the forecast period.

Avaliability of Substituents

However, patent expiry and entry of Clot-retrieval devices are among the factors that may impede the global market growth during the forecast period. Furthermore, the lack of approved treatments available and professionals are among the additional factors hampering the global market growth.

Segment Analysis

The global ischemic stroke treatment market is segmented based on drug class, route of administration, distribution channel and region.

Tissue Plasminogen Activator Drug Class is Expected to Dominate Market

Tissue plasminogen activator is an efficacious blood thinner and is authorized for the therapy of stroke. It enhances the probability of recovery. A number of investigations observed that individuals who receive tissue plasminogen activator during their ischemic stroke have additional potential to recover totally or have more infrequent possibilities of disability than those who do not consume the medicine. Therefore, for all patients with ischemic stroke, a tissue plasminogen activator is a first-line therapy to treat, boosting the segment growth.

Moreover, in January 2022, Thrombolytic Science, LLC was awarded a second patent by the United States Patent and Trademark Office for the innovative therapy of ischemic stroke via the usage of fibrinolytic enzymes, tissue plasminogen activator, tPA, and urokinase plasminogen activator, uPA. The recent patent authorization is expected to pave the path for the evolution of tissue plasminogen activator-based treatment of stroke.

Geographical Analysis

North America is Expected to Dominate the Global Market

It is expected that the North American market will dominate the global market for stroke and aneurysm treatment due to the increasing prevalence of these conditions in the region. According to the Centers for Disease Control and Prevention, over 795,000 individuals in the United States experience a stroke each year, with approximately 610,000 of these being first or new strokes.

Shockingly, there is an estimated one stroke every 40 seconds in the United States and every four minutes, someone dies from a stroke. Stroke cases are mainly of the ischemic type, accounting for around 87% of all strokes, which occur when blood flow to the brain is blocked. Additionally, about 1 in 50 people in the United States have an unruptured brain aneurysm, which translates to approximately 6.7 million individuals. The yearly rate of rupture is estimated to be around 8-10 per 100,000 individuals.

COVID-19 Impact Analysis

Due to the COVID-19 pandemic, elective and routine medical visits and examinations were postponed or discontinued to redirect resources toward providing emergent care for critically ill patients and to prevent the spread of the virus. Healthcare workers were stretched thin, leading to increased turnover rates among full-time and contract workers, which put a strain on the system and reduced the capacity to deliver clinical assistance, negatively impacting the market.

Market Segmentation

By Drug Class

• Tissue Plasminogen Activators (TPA)
• Anticoagulants
• Antiplatelets
• Statins
• Antihypertensives
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In September 2023, Sun Pharmaceutical Industrie's wholly-owned associate unit collaborated with US-based Pharmazz Inc to commercialise a drug utilized to treat cerebral ischemic stroke in India.
• In February 2023, the US Food and Drug Administration (FDA) has allocated a move ahead letter for Pharmazz's investigational new drug (IND) application to initiate a Phase III clinical trial of Sovateltide (PMZ-1620) in acute cerebral ischaemic stroke patients.

Competitive Landscape

The major global players in the market include: Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Sanofi, Daiichi Sankyo, AstraZeneca, Amgen Inc., Merck and Co. Inc. and Biogen Inc. among others.

Why Purchase the Report?

• To visualize the global ischemic stroke treatment market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of ischemic stroke treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global ischemic stroke treatment market report would provide approximately 61 tables, 59 figures and 194 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies